M&A / Deals RA Capital targets China with latest SPAC deal BioPharma DiveThe prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.M&A / DealsRead full story pharminent March 24, 2026 (Last updated: March 25, 2026) BioPharma Dive The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Immutrin raises $87M to advance drug for progressive heart diseaseNext: Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
